Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.92T
24h Vol:
$4.36B
Dominance:
MSFT:4.92%
Stocklytics Platform
Instrument logo  FUSN
Fusion Pharmaceuticals Inc
FUSN
54 / 100
$21.32arrow_drop_down0.16%-$0.03

Performance History

Stocklytics logo
Key Stats
Open$21.35
Prev. Close$21.36
EPS-1.45
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.80B
PE Ratio-
LOWHIGH
Day Range21.30
21.38
52 Week Range2.31
21.55
Ratios
P/B Ratio8.13
Revenue$2.06M
Operating M. %-4,798.45%
Earnings$0.00
Earnings Growth %-8.32%
EBITDA Margin %-1,000.00%
ROE %-49.34%
EPS-1.45

Score Breakdown

54vs 55. Market Avg.

All Score 54 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

FUSNMARKET
Value940
Quality4440
Ownership3517
Growth7145
Dividends-38
check_circle

Fusion Pharmaceuticals Inc's Price growth average in the last 3 years of 119.66% is great compared to market average of 6.47%. This indicates FUSN could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$751.62
24H (%)arrow_drop_down1.04%
24H ($)-$7.97
MARKET CAP$724.46B
PRICE$438.91
24H (%)arrow_drop_down0.63%
24H ($)-$2.81
MARKET CAP$414.91B
PRICE$147.57
24H (%)arrow_drop_down0.81%
24H ($)-$1.21
MARKET CAP$361.94B
PRICE$126.33
24H (%)arrow_drop_up0.14%
24H ($)$0.18
MARKET CAP$321.01B

About Fusion Pharmaceuticals Inc (FUSN)

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. John F. Valliant Ph.D.
Headquarters
Hamilton
Employees
101
Exchange
NASDAQ
add Fusion Pharmaceuticals Inc to watchlist

Keep an eye on Fusion Pharmaceuticals Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Fusion Pharmaceuticals Inc's (FUSN) price per share?

The current price per share for Fusion Pharmaceuticals Inc (FUSN) is $21.33. The stock has seen a price change of -$0.03 recently, indicating a -0.14% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Fusion Pharmaceuticals Inc (FUSN)?

For Fusion Pharmaceuticals Inc (FUSN), the 52-week high is $21.55, which is 1.03% from the current price. The 52-week low is $2.31, the current price is 823.38% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Fusion Pharmaceuticals Inc (FUSN) a growth stock?

Fusion Pharmaceuticals Inc (FUSN) has shown an average price growth of 119.66% over the past three years. It has received a score of 96 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Fusion Pharmaceuticals Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Fusion Pharmaceuticals Inc (FUSN) stock price performance year to date (YTD)?

As of the latest data, Fusion Pharmaceuticals Inc (FUSN) has a year-to-date price change of 157.92%. Over the past month, the stock has experienced a price change of 124.53%. Over the last three months, the change has been 122.42%. Over the past six months, the figure is 416.46%.

help
Is Fusion Pharmaceuticals Inc (FUSN) a profitable company?

Fusion Pharmaceuticals Inc (FUSN) has a net income of -$94.9M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 34.96% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -4.8K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.07M, with a revenue growth rate of 41.55%, providing insight into the company's sales performance and growth. The gross profit is $723K. Operating income is noted at -$99.23M. Furthermore, the EBITDA is -$97.89M.

help
What is the market capitalization of Fusion Pharmaceuticals Inc (FUSN)?

Fusion Pharmaceuticals Inc (FUSN) has a market capitalization of $1.81B. The average daily trading volume is 1.64M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.